{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-096268","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.623211+00:00","generated_at":"2026-05-30T01:48:57.222693+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Citius reports 27% ORR in Phase I trial of pembrolizumab + LYMPHIR for recurrent solid tumors","bullets":["27% objective response rate (4/15) and 33% clinical benefit rate; median PFS 57 weeks for patients with clinical benefit.","Trial enrolled 21 patients; three more to enroll before Phase I portion completes.","Combination well-tolerated; only one DLT (capillary leak syndrome) at 12 mcg/kg; no serious immune-related AEs.","Two of four partial responders had prior anti-PD-1 therapy, suggesting potential in checkpoint-resistant patients.","Phase II expansion planned across broader solid tumor types including gynecologic and other histologies."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-096268","json":"https://secwatch.observer/filing/0001213900-24-096268.json","markdown":"https://secwatch.observer/filing/0001213900-24-096268.md","text":"https://secwatch.observer/filing/0001213900-24-096268.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024096268/0001213900-24-096268-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024096268/ea0220670-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:48:57.222693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}